ArticleScientific reports2025
Elevated SGO2 expression in lung adenocarcinoma promotes migration and invasion via MAD2 and correlates with poor prognosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma is a globally prevalent malignant tumor with a high death rate, notorious for its invasive and metastatic capabilities. SGO2 is a key protein in the cell division process, influencing the development of various malignant tumors. However, research on the biological functions of SGO2 in Lung adenocarcinoma remains limited. By utilizing the Cancer Genome Atlas (TCGA) database, we performed an analysis of SGO2 expression levels in a cohort comprising 206 Lung adenocarcinoma patients in comparison to 200 non-neoplastic control specimens. Subsequently, we validated our findings through immunohistochemical staining in a subset of 21 Lung adenocarcinoma cases from Nanjing Second Hospital. Furthermore, the functional role of SGO2 in the H1299 cell line was assessed through a series of experiments including Western blotting, CCK-8 assays, Transwell assays for invasion, wound healing assays, and flow cytometric analysis. The study also explored the influence of SGO2 on the regulation of MAD2 expression. The enhancement of SGO2 expression in Lung adenocarcinoma tissues was significantly associated with a poor prognosis in patients. A reduction in SGO2 expression markedly decreased the proliferative, migratory, and invasive capabilities of H1299 cells, a phenomenon that may be attributed to the regulation of MAD2 expression by SGO2. SGO2 exerted a pivotal influence on the metastatic behavior of Lung adenocarcinoma cells by governing the expression of MAD2, thereby contributing substantially to the molecular pathogenesis of Lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.